cho_logo_symbol_border

Latest News

Revolutionary Lifileucel Therapy: A New Era in Metastatic Melanoma Treatment

The recent FDA accelerated approval of lifileucel, known commercially as Amtagvi, marks a groundbreaking development in cancer therapy. This treatment is the first of its kind, a tumor-derived autologous T cell immunotherapy, specifically targeting patients with unresectable or metastatic melanoma who have undergone prior treatments. This

Read More

Identifying Early Warning Signs of COVID-19 Before Testing Positive

As we navigate the chilly months of winter, we’re not just braving the cold but also a variety of respiratory illnesses, including COVID-19. Recent trends indicate a slight decrease in COVID-19 cases. For instance, hospital admissions have dropped from around 35,000 per week to approximately 20,000,

Read More

Clear Health Pass™ Launches Revolutionary COVID Pet Test™ at VMX

Protecting Our Furry Companions at the 40th Annual Veterinary Meeting & Expo (VMX) In 2023, we estimate that 76 million US pet owners will be infected with COVID-19, making the COVID Pet Test™ a vital tool in the fight against COVID-19”— John Cataldi, CEO of Clear

Read More

New England Sees Rapid Rise in Immune-Evading COVID Variants BQ.1, BQ.1.1

As various strains of Omicron have started popping up all over the US, New England has specifically seen a jump in BQ.1 and BQ.1.1: “New England has seen a rapid rise in the frequency of new immune-evading COVID-19 variants BQ.1 and BQ.1.1, with the rate of cases nearly doubling

Read More

Omicron subvariants reflect a ‘viral evolution on steroids’

Each day we move closer to the next wave of COVID, here’s the latest about the new variants and what to expect this coming season: “An omicron subvariant is once again demonstrating immune-dodging abilities, posing a threat to both vaccinated and previously infected individuals. A report

Read More

The XBB family of Omicron has landed in the U.S. Here’s what it means for this fall’s COVID wave

Here’s what we know about the latest omicron variant’s emergence in the United States: “XBB—a new, extremely immune-evasive Omicron variant surging in Singapore—hasn’t yet been detected in the U.S. But its child has. XBB.1 was first detected in the U.S. on Sept. 15 and made up

Read More

New Omicron Strain Demonstrates “Dramatic” Resistance To Antibody Immunity

When the coronavirus pandemic first struck, opinions of how to combat it typically involved some form of mass “natural immunity” or vaccination. New variants unfortunately seem to have mutations that help it evade both, which is becoming cause for concern: “An emerging Omicron subvariant has raised

Read More

The Nightmare COVID Variant That Beats Our Immunity Is Finally Here

Unfortunately, scientists and virologists have expected this date to come for some time. New subvariatns of Omicron have concerning new mutations: “A new subvariant of the novel-coronavirus called XBB dramatically announced itself earlier this week, in Singapore. New COVID-19 cases more than doubled in a day, from 4,700 on

Read More

The next U.S. COVID wave is coming. Why it will be ‘much weirder than before.’

As COVID has continued to mutate, various mutations are causing outbreaks in different parts of the world, this, among other complicating factors may bring us into a strange season for our health: “In recent weeks, COVID trackers have suddenly been subjected to a dizzying barrage of

Read More

As Omicron mutates wildly the virus shows first signs of convergent evolution

Convergent evolution is defined by the following, “In evolutionary biology, convergent evolution is the process whereby organisms not closely related (not monophyletic), independently evolve similar traits as a result of having to adapt to similar environments or ecological niches.” Interesting changes in virus that causes COVID-19

Read More

 

Our Journey to $1B+ Valuation

 

Disrupting Healthcare Testing / Diagnostics Early Detection of Cancer,
Chronic Conditions, Disease, Unlocking Anti-Aging Genomics & Promoting Longevity.

 

FUNDING GOAL $20,000,000

Funding Goal $20,000,000

20%

Skip to content